Equities analysts expect Proteostasis Therapeutics, Inc. (NASDAQ:PTI) to post $1.38 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Proteostasis Therapeutics’ earnings. The lowest sales estimate is $1.03 million and the highest is $1.72 million. Proteostasis Therapeutics reported sales of $1.72 million in the same quarter last year, which indicates a negative year-over-year growth rate of 19.8%. The company is expected to announce its next quarterly earnings report on Thursday, November 9th.

On average, analysts expect that Proteostasis Therapeutics will report full-year sales of $1.38 million for the current financial year, with estimates ranging from $2.17 million to $5.50 million. For the next year, analysts forecast that the company will post sales of $2.00 million per share. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Proteostasis Therapeutics.

PTI has been the topic of a number of analyst reports. Zacks Investment Research cut Proteostasis Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, May 30th. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Proteostasis Therapeutics in a research note on Friday, June 30th. Finally, Leerink Swann reissued an “outperform” rating and set a $9.00 target price (down from $17.00) on shares of Proteostasis Therapeutics in a research note on Wednesday, August 16th.

Shares of Proteostasis Therapeutics (NASDAQ:PTI) opened at 1.99 on Friday. The stock’s market capitalization is $49.95 million. Proteostasis Therapeutics has a one year low of $1.71 and a one year high of $16.67. The stock has a 50 day moving average of $2.08 and a 200-day moving average of $5.13.

ILLEGAL ACTIVITY NOTICE: “$1.38 Million in Sales Expected for Proteostasis Therapeutics, Inc. (PTI) This Quarter” was reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/09/22/1-38-million-in-sales-expected-for-proteostasis-therapeutics-inc-pti-this-quarter-3.html.

Large investors have recently added to or reduced their stakes in the stock. Trexquant Investment LP lifted its holdings in Proteostasis Therapeutics by 1.0% during the 1st quarter. Trexquant Investment LP now owns 19,790 shares of the company’s stock valued at $155,000 after purchasing an additional 190 shares during the last quarter. Teachers Advisors LLC lifted its holdings in Proteostasis Therapeutics by 21.4% during the 4th quarter. Teachers Advisors LLC now owns 12,617 shares of the company’s stock valued at $155,000 after purchasing an additional 2,223 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Proteostasis Therapeutics by 17.3% during the 1st quarter. Bank of New York Mellon Corp now owns 34,964 shares of the company’s stock valued at $273,000 after purchasing an additional 5,153 shares during the last quarter. Russell Investments Group Ltd. acquired a new stake in Proteostasis Therapeutics during the 1st quarter valued at $100,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in Proteostasis Therapeutics during the 1st quarter valued at $112,000. 73.71% of the stock is owned by institutional investors and hedge funds.

About Proteostasis Therapeutics

Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.

Get a free copy of the Zacks research report on Proteostasis Therapeutics (PTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Proteostasis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.